Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview and connect with your local pharmacy team to learn more.
Brand name drug launches*
Exxua™ (Gepirone ER)
- Indicated for: Treatment of major depressive disorder (MDD) in adults.
- Dosage form: Oral extended-release tablets.
- Status: Expected early 2024.
Generic drug launches*
Risperdal Consta® (Risperidone ER injectable powder kit)
- Indicated for: Treatment of schizophrenia and other behavioral health conditions, such as bipolar disorder.
- Dosage form: Long-acting injection.
- Status: Available now.
Current drug shortages*
Brand:
Advair Diskus 100/50, 250/50 and 500/50
- Indicated for: Treatment of asthma and/or chronic obstructive pulmonary disease (COPD).
- Status: Recovery TBD.
Zyprexa Relprevv
- Indicated for: Treatment of schizophrenia in adults.
- Status: Estimated recovery June 2024.
Generic:
Buproprion XL
- Indicated for: Treatment of depression.
- Status: Recovery TBD.
Naltrexone
- Indicated for: Treatment of alcohol and/or opioid use disorder.
- Status: Recovery TBD.
Lidocaine 5% patches
- Indicated for: Localized pain control and/or postherpetic neuralgia.
- Status: Recovery TBD.
People-first, full-service pharmacy
Stay connected!
For regular updates on drug trends, shortages, and other behavioral health news, subscribe to Genoa’s newsletter and sign up for event and insights notifications. Looking for more information on Genoa and our pharmacy services? Contact us and we’ll be in touch.
*Information on this page was accurate at the time of posting. Shortage recovery dates are only estimates. These estimates are based on the distribution information that Genoa has access to.
